Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity

2021/01/28 by Dianne K. Bryce, Chris M. Ware, C. Ware +16 · 7 citations
Medicine · Neuroscience · #Parkinson's Disease Mechanisms and Treatments #Cholinesterase and Neurodegenerative Diseases #Nuclear Receptors and Signaling

paper · pdf · doi:10.1124/jpet.120.000217

Citations

• MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Cited by

• Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. [europepmc]
• LRRK2 and idiopathic Parkinson's disease. [europepmc]
• Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2. [europepmc]
• Perspective on the current state of the LRRK2 field. [europepmc]
• G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage. [europepmc]
• LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression. [europepmc]
• Mitochondrial organization in the developing proximal tubule is controlled by LRRK2. [europepmc]